Hims & Hers offers rare high growth at value pricing, with DCF models pointing to major upside despite volatility and short ...

Hims & Hers delivered impressive Q1 2025 results, with 111% y/y revenue growth and 38% y/y subscriber growth. Check out why I ...

Short interest in Hims & Hers Health Inc rose to a record high, even as shares surged following strong first-quarter results.

An ad for compounded versions of weight-loss drug semaglutide by telehealth company Hims & Hers has attracted the ire of a pharmaceutical trade organisation that calls the campaign "nothing short ...

Nikkei 225 is an index which belongs to the Tokyo Stock Exchange (TSE). The Nihon Keizai Shimbun (Nikkei) calculates the index daily since 1950. The calculation of Nikkei 225 index began on ...

The latest headlines from Newswires.